Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 20, 2020

Primary Completion Date

November 20, 2020

Study Completion Date

December 10, 2020

Conditions
SARS Pneumonia
Interventions
BIOLOGICAL

Convalescent Plasma of patients with COVID-19

Convalescent Plasma from patients with covid-19 by Apheresis, the maximum plasma volume withdrawn per session should not exceed 600 mL, excluding the anticoagulant volume, or 16% of the total blood volume, in the absence of volumetric replacement.

OTHER

placebo (hartmann plus albumine)

use of albumin 20% in 250cc of Hartmann solution

Trial Locations (2)

04470

Hospital Nava de Alta Especialidad, Mexico City

06720

Hospital General de Mexico Dr Eduardo Liceaga, Mexico City

All Listed Sponsors
collaborator

Hospital General Naval de Alta Especialidad - Escuela Medico Naval

OTHER_GOV

collaborator

National Institute of Pediatrics, Mexico

OTHER_GOV

collaborator

Instituto Nacional de Enfermedades Respiratorias

OTHER_GOV

lead

Grupo Mexicano para el Estudio de la Medicina Intensiva

OTHER

NCT04405310 - Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial | Biotech Hunter | Biotech Hunter